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Abstract
Background: To assess whether early health economic modeling helps to distinguish those healthcare innovations that 
are potentially cost-effective from those that are not potentially cost-effective. We will also study what information is 
retrieved from the health economic models to inform further development, research and implementation decisions.
Methods: We performed secondary analyses on an existing database of 32 health economic modeling assessments of 
30 innovations, performed by our group. First, we explored whether the assessments could distinguish innovations 
with potential cost-effectiveness from innovations without potential cost-effectiveness. Second, we explored which 
recommendations were made regarding development, implementation and further research of the innovation. 
Results: Of the 30 innovations, 1 (3%) was an idea that was not yet being developed and 14 (47%) were under development. 
Eight (27%) innovations had finished development, and another 7 (23%) innovations were on the market. Although all 
assessments showed that the innovation had the potential to become cost-effective, due to improved patient outcomes, 
cost savings or both, differences were found in the magnitude of the potential benefits, and the likelihood of reaching 
this potential. The assessments informed how the innovation could be further developed or positioned to maximize its 
cost-effectiveness, and informed further research.
Conclusion: The early health economic assessments provided insight in the potential cost-effectiveness of an innovation 
in its intended context, and the associated uncertainty. None of the assessments resulted in a firm ‘no-go’ recommendation, 
but recommendations could be provided on further research and development in order to maximize value for money. 
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Implications for policy makers
• Early health economic modeling provides insight in potential cost-effectiveness of a healthcare innovation in its intended context, and the 
associated uncertainty. 
• This can be applied before and during the development of an innovation.
• Of the 32 modeling assessments that were retrospectively analyzed, none resulted in a firm ‘no-go’ recommendation because they all could 
potentially become cost-effective by improving health and/or saving costs.
• The assessments did provide insights in how to proceed, both in terms of development and positioning of the innovation and further research, 
in order to maximize value for money. 
• This implies a shift away from traditional use of health economic modeling with the aim of estimating the exact cost-effectiveness of a 
technology, towards exploring what is needed for a technology to provide most value for money.
Implications for the public
The value an innovative health technology may ultimately bring to healthcare systems is defined at an early stage. Health economic modeling can 
be used in this early stage to synthesize evidence on the current standard of care and compare this with a hypothetical care pathway that includes 
the technology. This provides insight in the potential value for money the innovation can bring in its intended context, as well as the associated 
uncertainty, and informs further research and development. None of the 32 assessments we retrospectively explored resulted in a firm ‘no-go’ 
recommendation, but recommendations could be provided on further research and development in order to maximize value for money. 
Key Messages 
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Introduction
Novel health technologies are being developed at a dizzying 
pace. 3D printing, biomarkers, genomics and robotics are 
only some examples of innovative trends. Such innovations 
are widely assumed to be positive in their effects, to the 
extent that the term ‘innovative’ usually expresses unqualified 
praise.1 Yet, the need to avoid unnecessary innovations and 
manage the transition for necessary innovations, is among the 
most important challenges facing health systems today.2
Health economic modeling has traditionally been applied 
to new health technologies as a reimbursement decision tool 
once the technology had satisfied regulatory approval, and 
evidence on costs and consequences is available. It can then 
act as a means to synthesize available evidence and estimate 
the resulting uncertainty.3 However, this might not be the first 
opportunity in the technology lifecycle for this evaluation to 
occur.4 Over the last 2 decades, there has been an increasing 
interest in using health economic modeling in earlier stages 
of technology development, to inform product development, 
market access, and pricing.5 In this so-called early health 
technology assessment (HTA), which includes early health 
economic modeling, the focus is often on the ‘commercial 
viability’ of new technologies.6-10 This is deemed to allow 
companies to stop further development if results suggest that 
the product is unlikely to become cost-effective. Ijzerman et al 
refer to this as “fail fast, fail cheap.”5
Especially in such early stages, technology can still be 
developed in many different ways.2 Lehoux and colleagues 
recently published the results of their 5-year qualitative 
research program examining health innovation processes. 
They suggest that “early HTA and coverage with evidence 
development initiatives could provide technology developers 
with useful input regarding the decisions they make.”2 These 
decisions may transcend the go/no-go decision that is the 
current focus of early HTA.5,10,11 To date, such a larger role 
for early HTA is not yet formally substantiated with empirical 
evidence. 
Over the past 4 years, through a subsidiary company of 
our university hospital, we have performed 32 early-stage 
health economic modeling assessments. The aim of this study 
is to explore whether these assessments help to distinguish 
those innovations that are potentially cost-effective from 
those that are not potentially cost-effective. Additionally, 
we explore what information is retrieved from the health 
economic models to inform further development, research 
and implementation decisions.
Methods
Description of the Assessments 
We retrospectively analyzed the first 32 early-stage health 
economic modeling assessments performed by our group. 
These assessments related to 30 innovations. Innovations 
were assessed if they had the aim to improve patient health, 
and if a stakeholder commissioned a health economic 
modeling assessment. Two innovations (#16 and #19 in the 
Table) were assessed twice, exploring different scenarios for 
the positioning of the innovation in the care pathway. The 
assessed innovations were aimed at improving healthcare 
over a wide range of diseases, such as cancer, diabetes, 
pregnancy-related complications and asthma (Supplementary 
file 1). They were all non-drug technologies, relating to the 
screening (n = 5), diagnosis (n = 11) or treatment (n = 14) of 
patients (Table). 
In each of the 32 assessments, a deterministic health 
economic model was built. The models were conceptualized 
and validated in accordance with the modeling good research 
practices.12,13 Each model was informed and validated through 
interviews with independent clinical experts and where 
relevant with other stakeholders. The models were either 
state transition models or decision trees, or a combination 
of the 2. Most of the assessments (91%) were commissioned 
by medical device companies, generally small to medium 
enterprises. The other 3 assessments were commissioned by 
clinicians and/or clinical departments within our hospital. 
The commissioner of the assessment will further be referred 
to as ‘client.’
In these 32 health economic modeling assessments, 
evidence from published literature was synthesized to 
estimate the costs and effects of the current care pathway. If a 
parameter could not be informed by evidence, estimates were 
obtained from independent clinical experts and varied in 
sensitivity analyses. To estimate potential cost-effectiveness, 
costs were calculated from a Dutch healthcare perspective, 
unless the client requested a different perspective. Where 
possible, effectiveness was measured in terms of quality-
adjusted life years (QALYs). Costs and effects were discounted 
in adherence to the guidelines for economic evaluation from 
the relevant jurisdiction. 
Different analyses had been performed to assess the 
potential value of an innovation, depending on the question 
of the client and the availability of evidence. First, if the costs 
and effects of the innovation were unknown, effectiveness gap 
or headroom analysis was performed to explore the maximum 
potential value of an innovation.6 Here, care as usual is 
compared with the perfect situation that the innovation could 
– in theory – achieve. The difference in costs and effects 
represents an upper bound of the potential cost-effectiveness 
of the innovation. Second, if the costs of an innovation or 
its effects were known, threshold analysis was performed.14 
Here, we searched for the minimum effectiveness that is 
needed for the innovation to be cost-effective, given its costs. 
Or, we searched for the maximum costs of the innovation 
given its effectiveness. Third, scenario analysis was used to 
develop descriptions of how the future may unfold based 
on ‘if-then’ propositions, and to evaluate the consequences 
of these descriptions in terms of costs and effects.15 In these 
scenarios we explored cost-effectiveness of the innovation 
under different assumptions of costs, effectiveness or for 
example a different subpopulation or positioning in the care 
pathway. Fourth, if clinical evidence on costs and effects of 
the innovation was available, ‘standard’ cost-effectiveness 
analysis was performed based on this evidence. Additionally, 
in all assessments uncertainty about care as usual was handled 
by means of deterministic sensitivity analysis. Since the 
current study involves a retrospective analysis of completed 
assessments, no additional analyses of (potential) cost-
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effectiveness were performed for this study.
Analysis of the Assessments
First, we determined the development phase of the innovation 
at the time of assessment. Four development phases were 
distinguished. First, in the ‘idea screening’ phase the 
innovation is not yet being developed, but only consists of an 
innovative idea. Second, in the ‘concept development’ phase 
a first version of the innovation is being developed. Third, in 
the ‘pre-market’ phase a product is available, for example for 
clinical research, but the innovation is not yet on the market. 
Finally, in the ‘market access’ phase the innovation has entered 
the market and is used in clinical practice. 
Second, from the 32 assessments we retrospectively 
retrieved what types of decisions were informed, and how. For 
this purpose we first explored whether the assessments found 
the innovations to have potential to become cost-effective or 
not. An innovation had the potential to become cost-effective 
if it could yield both health benefit and cost savings, or if it had 
the potential to remain below the relevant cost-effectiveness 
threshold. For example, most innovations were assessed from a 
Dutch healthcare perspective and thus compared to the Dutch 
cost-effectiveness threshold of €20 000 to €80 000 per QALY.16 
As Chapman et al put it, early health economic modeling 
can be used to inform developers “to avoid investment in 
devices that could never be cost-effective.”11 If possible, we 
calculated the percentage of innovations that could never be 
cost-effective. Second, we explored which other insights were 
obtained from the assessments. We categorized these into 
insights for further development and/or implementation, and 
insights for further research. Where possible, these categories 
were further specified to identify clusters of specific types of 
insights. For each of these clusters, percentages and examples 
were provided.
The assessments were independently analyzed by 2 authors 
(JG, TG). Discrepancies were resolved in a consensus meeting 
with a third author (JN).
Results
Phases of Development 
Of the 30 innovations, 1 (3%) was in the idea screening phase 
and had not yet started its development (Figure 1).
Here, the room for improvement (headroom) was assessed, 
accompanied with scenario analyses (Supplementary file 1). 
This assessment is described in more detail in Supplementary 
file 2, to illustrate the different types of analyses that were 
Table. Overview of the Assessments, Innovations and Retrieved Informationa
Assessment # Type of Innovation Development Phase Clinical Data on Innovation Available? Further Development Further Research
1 Diagnosis Pre-market No Positioning Value proposition
2 Treatment Pre-market Yes - Value proposition
3 Screening Concept development No Positioning Value proposition
4 Treatment Concept development No Value proposition Value proposition
5 Treatment Concept development No Positioning -
6 Diagnosis Market access Yes Positioning Value proposition
7 Treatment Market access No - Value proposition
8 Diagnosis Pre-market No - Value proposition
9 Screening Concept development No Development Value proposition
10 Diagnosis Concept development No Positioning Value proposition
11 Treatment Idea screening No Development -
12 Treatment Concept development No Value proposition Value proposition
13 Diagnosis Market access Yes Positioning -
14 Treatment Pre-market No Value proposition Value proposition
15 Treatment Concept development No Positioning Value proposition
16a Screening Pre-market Yes Positioning Value proposition
16b Same innovation as 16a Positioning Value proposition
17 Diagnosis Concept development No Positioning Usual care
18 Treatment Concept development No Positioning Value proposition
19a Diagnosis Pre-market Yes Positioning -
19b Same innovation as 19a Positioning -
20 Diagnosis Concept development No Positioning Value proposition
21 Screening Concept development No Positioning Value proposition
22 Treatment Concept development No Positioning Value proposition
23 Treatment Market access Yes Value proposition Patient benefit
24 Diagnosis Market access Yes Positioning Patient benefit
25 Diagnosis Market access No Positioning Value proposition
26 Treatment Pre-market No Positioning Value proposition
27 Treatment Pre-market No Positioning Value proposition
28 Screening Concept development No Positioning Value proposition
29 Treatment Market access No Value proposition Value proposition
30 Diagnosis Concept development No Positioning Value proposition
a More detailed information on the innovations and assessments can be found in Supplementary file 1.
Grutters et al
International Journal of Health Policy and Management, 2019, 8(10), 575–582578
performed. For 14 (47%) innovations that were in the phase 
of development and not yet studied in patients, headroom, 
scenario and threshold analyses were performed. In general, 
multiple types of analyses were combined in one assessment. 
For example, we explored under which circumstances the 
innovation could provide value for money (threshold analysis), 
as well as an analysis to explore what if the innovation had 
a specific effectiveness (scenario analysis). Another 8 (27%) 
innovations had finished development and were planning or 
performing clinical (pilot) studies. For 3 of these innovations, 
some clinical data on the performance of the innovation 
was already available. Here, standard (preliminary) cost-
effectiveness analyses were performed. For example, data 
on accuracy of a novel diagnostic test were combined with 
published literature on the implications of false negative 
and false positive results. Seven (23%) innovations were in 
the market access phase. For 4 of these innovations some 
evidence on its performance was available. Depending on 
the availability of evidence, (preliminary) cost-effectiveness 
analyses or threshold/scenario analyses were performed. 
Distinguishing Between Innovations With and Without 
Potential Cost-Effectiveness
Of the 32 early assessments performed by our group, all 
showed that the innovation could potentially become cost-
effective, due to improved patient outcomes, cost savings 
or both. Innovations for which we could not estimate the 
potential benefit in terms of QALYs, were deemed potentially 
cost-effective because they potentially resulted in both cost 
savings and health gain. Hence, for none of the innovations 
we could conclude that it could never become cost-effective, 
and thus none of the assessments resulted in a firm no-go 
recommendation. 
We did find that the assessments were helpful in gaining 
insight in the potential cost-effectiveness of the innovation in 
its intended context. For example, we assessed the potential 
cost-effectiveness of an innovative device (#26) that aimed 
to prevent side effects caused by first-line treatment. Patients 
with side effects generally stop treatment or receive a lower 
dose, both resulting in a lower total treatment dose. Reducing 
side effects would therefore increase the dosage of this first-
line treatment to the total dose that was recommended in 
the guideline, resulting in an increase in costs. Very recent 
studies however showed that on average this increase to the 
recommended total dose for these specific patients did not 
increase efficacy or improve health. Thus, the innovation 
could yield some cost reduction and health benefit due to a 
reduction in side effects, but this would come at the high cost of 
increased dose of expensive first-line treatment. Although this 
might be deemed ‘unfair,’ as the innovation cannot be blamed 
for the fact that in these patients first-line treatment does not 
provide value for money, the (potential) cost-effectiveness of 
an innovation is always dependent on its context. Therefore, it 
is important for developers to understand this context and to 
know in an early stage of development what the potential cost-
effectiveness of their innovation might be, and which factors 
influence this cost-effectiveness. Of course, health economic 
modeling is only one tool to understand this context, and 
interviews with stakeholders to build and validate the model 
are essential in this respect.
Informing Further Development or Implementation
In 2 (6%) assessments no recommendations were provided on 
further development (Figure 2).
The other 30 (94%) assessments informed how the 
innovation should be further developed or implemented 
to enhance the cost-effectiveness of the innovation. Three 
assessments specifically focused on further development. One 
of these was a screening tool (#9), where the assessment clearly 
showed that the impact of the innovation could be increased 
by increasing specificity. This informed the developers that 
they should set their cut-off values in a way that allowed 
optimal specificity. Another was an innovation that aimed 
to reduce under- and overtreatment by improving patient 
compliance to medication (#11). During the assessment we 
found evidence that a lower dose did not result in disease 
progression. Hence, reducing under-treatment would result 
in high costs without yielding health benefits. Based on this 
information we recommended to develop the innovation in a 
way that the focus was on reducing overtreatment. 
Most (69%) of the assessments showed how decisions on 
positioning of the innovation in the care pathway impacted 
its cost-effectiveness. Positioning could concern the target 
population or the place the innovation has in a care pathway, 
which could also be related. For example, for a diagnostic 
innovation for bladder cancer (#19) we modeled the potential 
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Figure 1. Overview of the Phases of Development at the Time of Assessment.
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consequences of implementation of the innovation before 
and after a standard diagnostic test. We found that for specific 
subgroups of patients most value for money was expected 
when implementing the innovation before the standard test, 
while for other subgroups most value for money could be 
achieved when the innovation was used after the standard 
test. These subgroups were based on symptoms of the disease, 
and thus the cost-effectiveness of the innovation could be 
maximized if the positioning of the innovation is tailored to 
the presence of these symptoms. 
Another example was an add-on therapy for cancer 
treatment (#27). This could be added to the alternative 
(second-line) treatment to increase its effectiveness. We 
explored the potential health economic consequences of the 
innovation added to second-line treatment for 3 different 
implementation strategies: (1) as an alternative to first-line 
treatment, (2) as an alternative to second-line treatment 
without the innovation, and (3) as an alternative to first-line 
treatment only if this was unavailable due to delivery issues, 
which was a realistic problem. In addition, we explored the 
consequences of a strategy in which we added the innovation 
to second-line treatment with the aim to give patients half the 
treatment dose patients receive now. Each strategy thereby 
represented a possible positioning of the innovation in the 
care pathway. This analysis clarified the potential risks and 
benefits of each scenario, and therefore informed the decision 
on how to position the innovation. We found that it was not 
worthwhile to use the innovation to reduce the treatment 
dose, as this would only result in limited health benefit at 
increased costs. We also found that adding the innovation 
to second-line treatment for patients who are intolerant or 
do not respond to first-line treatment (strategy 2) has most 
potential value. 
Five (16%) of the assessments resulted in recommendations 
on the innovation’s value proposition, ie, how the developers 
propose the innovation to add value to the standard of care. 
For example, we assessed the potential value of an innovation 
that aimed to reduce the time needed for a specific part of a 
procedure (#4). We found that the health benefit of reducing 
time for this part of the procedure was limited and uncertain. 
Hence, we advised the clients to shift the value proposition 
to a different procedure or aim, such as improved precision. 
Informing Further Research
Most (75%) of the assessments recommended to perform 
empirical research to (further) validate the value proposition 
(Figure 3).
In these assessments we found that the innovation was 
potentially cost-effective. However, as for most innovations no 
or limited clinical evidence on their effectiveness was available, 
we recommended to empirically study this effectiveness 
to assess the actual cost-effectiveness of the innovation. 
For example, developers of an innovation claimed that the 
innovation could increase medication adherence (#12). The 
assessment showed that if this could be realized, this would 
result in considerable cost savings and health benefits. The 
recommended next step was therefore to study the percentage 
of adherence that could be increased, and its consequences. 
With the use of scenario and sensitivity analyses the 
assessments allowed for very specific recommendations on 
the target population, outcome measures and time horizon 
that should be used in future studies. 
Also, specific recommendation on research into parts 
of the value proposition were provided. For example, 
for an innovative screening tool (#16) we found that the 
participation rate was considerably influencing its potential 
cost-effectiveness. Hence, it was important that studies 
investigated – next to accuracy of the tool – what a realistic 
participation rate would be. This might require different 
study designs, such as qualitative research, surveys or discrete 
choice analysis. For some innovations we showed that it was 
important not only to study whether an innovation works, but 
also to study whether this can result in improved health. It is 
often possible to study the relationship between the direct aim 
of the innovation (eg, reduced complications) and improved 
health, even before developing and studying the specific 
innovation. Since the cost-effectiveness of the innovation 
is dependent on the consequences of its aim (eg, the health 
gain through reducing complications), it was sometimes 
recommended to study these consequences before further 
developing the innovation and studying whether it works. 
Related to this, one assessment (3%; #17) recommended 
to perform further research into the current care pathway, to 
better determine the effectiveness gap (ie, difference between 
current effectiveness and a hypothetical perfect situation). 
Here, the uncertainty about the effectiveness gap was found 
to be too high to draw valid conclusions on the potential 
cost-effectiveness of the assessment. The assessment revealed 
specifically which lacking information was influential and 
should thus be collected. 
Figure 2. Overview of the Recommendations for Development or Implementation.
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For the 7 innovations where some effectiveness data were 
already available, the assessments showed the importance 
of measuring for example patient-related outcomes, or 
performing better quality studies into effectiveness and/or 
societal impact. Two innovations (6%) with performance 
data – both diagnostic innovations – were deemed to have 
sufficient evidence on cost-effectiveness for widespread 
implementation.
In 2 other assessments (6%) that did not recommend 
further research, the recommendation was to further develop 
the innovation or change the value proposition, before 
conducting further research.
Discussion
Our exploration of 32 early health economic assessments 
resulted in 3 main insights. First, we found that all 30 
innovations could potentially become cost-effective. The 
assessments did provide insight in the size and uncertainty 
of the potential cost-effectiveness of the innovation in its 
intended context. Second, we found that the assessments were 
helpful in informing how the innovation could be further 
developed or should be positioned to maximize its value for 
money. Third, we found that the assessments were helpful 
in steering further research, with specific recommendations 
made for endpoints, types of studies and target populations.
In previous studies, Markiewicz et al10 and Chapman 
et al11 concluded that early health economic modeling is 
able to distinguish favorable and unfavorable innovations. 
Although we found differences between innovations in 
the magnitude of the potential cost-effectiveness, and the 
likelihood of reaching this potential, we were not able to 
dismiss any of the 30 innovations because they all were 
potentially cost-effective through improving health and/or 
saving costs. With our analyses we informed the clients on 
this magnitude and likelihood, as well as on how they can best 
continue development to maximize the cost-effectiveness of 
the innovation. Also, we found that commercial viability, 
or potential value of an innovation comprises more than 
whether it has the potential to become cost-effective 
compared with care as usual. Budget impact, meeting 
needs of patients or clinicians, risks, competing upcoming 
innovations and logistical issues may limit the commercial 
viability of an innovation, even if it is potentially cost-
effective. Although these broader criteria were not quantified 
in the health economic models, these were encountered in the 
accompanying interviews and included in the assessments 
reports. For example, one innovation resulted in only limited 
cost savings per patient and no health benefit. However, as 
the innovation would be applied in a large patient population, 
and its expected costs are limited, it could result in large 
savings for society. For some innovations there was potential – 
theoretical – value, but it was deemed very difficult to achieve 
this value. Pursuing innovation would thus be risky as the 
probability that the innovation would become cost-effective 
was deemed low. Here, we advised developers to reconsider 
whether it was worth taking this risk. 
It is known that there are many challenges for 
implementation of a health innovation.1,17 As Lehoux et 
al show, many of these challenges characterizing the later 
phases of development (eg, implementation or diffusion), 
are determined at a much earlier stage.2 We found that early 
health economic modeling can help to identify at least some 
of these challenges in an early stage, to allow for development 
and research to be tailored to address these potential barriers. 
One specific barrier that we encountered several times was 
that an innovation would result in reallocating care from 
one clinical specialty to another. Or, that a relatively cheap 
device could potentially obviate expensive surgery. However, 
the expensive surgery was reimbursed, whereas the device 
was not. As a result, use of the device would cost the hospital 
money, and while it could potentially result in considerable 
societal savings, these savings would not benefit the hospital. 
This makes it difficult to implement the device in the hospital. 
These examples emphasize the importance of understanding 
the (financial) context of the healthcare setting the innovation 
is going to be positioned in. Using stakeholder interviews to 
inform the health economic modeling assessment can help to 
yield important information about this context.18
Our study also has some limitations. First, our study is 
a retrospective analysis 32 early-stage health economic 
modeling assessments performed by a subsidiary company 
of our university hospital. Almost all assessments were 
commissioned by the developers of the innovation, and 
contain sensitive information about the innovation and its 
potential cost-effectiveness. To date, only 2 of the assessments 
were published.19,20 Due to the confidentiality of the 
 
Figure 3. Overview of the Recommendations for Further Research.
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information, we were limited in the amount of information 
we could provide on the assessments. Confidentiality is often 
an issue in early HTA, when commercial viability is assessed. 
However, we believe it is important to share experiences such 
as these to improve the use and methodology of early HTA. 
Second, the innovations analyzed here represent a 
selected sample of innovations for which an early health 
economic modeling study was commissioned. This may 
have overestimated the potential cost-effectiveness, because 
developers of these innovations are sufficiently confident to 
commission an early economic modeling study. On the other 
hand, one could argue that it is an underestimation, because 
for the medical technologies with most potential value 
implementation in practice is easy and a health economic 
modeling study would not be commissioned. It is unclear if 
repeating this study in another setting would result in similar 
findings. However, we expect that headroom analysis, being a 
best-case and often unrealistic scenario, will hardly ever result 
in firm ‘no-go’ decisions. We encourage others to share similar 
empirical research on early health economic modeling, to 
corroborate or disprove our findings. Third, the innovations 
varied in their phases of development. It is questionable 
whether the assessments of the innovations that were in the 
market access phase can be defined as ‘early.’ Ijzerman et al 
define early HTA as “all methods used to inform industry and 
other stakeholders about the potential value of new medical 
products in development, including methods to quantify 
and manage uncertainty.”5 They add that this definition 
“includes early HTA of medical products just before and 
also at the early stages of clinical use, while accepting that 
product development can continue after regulatory approval”. 
With this addition, all of our assessments can be defined as 
‘early.’ Fourth, we did not provide results of the assessments 
in terms of expected costs or effects, or cost-effectiveness 
estimates. Besides issues of confidentiality mentioned 
earlier, we feel that insight in potential consequences, and 
the relationship between assumptions and consequences 
were much more important than a point estimate. Also, the 
point estimate cannot be judged without the context of the 
analysis performed, the quality of the evidence underlying 
the assessment, the likelihood of an innovation reaching its 
potential and so on. Fifth, related to the quality of evidence, 
we addressed uncertainty surrounding care as usual only 
by means of deterministic sensitivity analyses. Ideally, 
we would have combined deterministic and probabilistic 
sensitivity analyses to best address the existing uncertainty 
and its interrelatedness.14 However, in this early stage it 
is difficult to quantify the (non-statistical) uncertainty 
surrounding the costs and effectiveness of the innovation in 
distributions. Probabilistic sensitivity analyses in this case 
can cause pseudo-certainty of the results generated and may 
therefore be misleading.21 For an audience without expertise 
in economic evaluation, we feel that scenario and threshold 
analyses, as well as deterministic sensitivity analyses, for 
example presented in tornado diagrams, are most informative 
in providing insight in the factors that most impacted the 
cost-effectiveness of the innovation. Sixth, while we clustered 
the different insights, these were not as black and white as 
presented here. Generally, assessments provided multiple 
recommendations and these may relate to different clusters. 
We here presented the most important insights, but these can 
also not be interpreted as being independent. For example, 
the value proposition is often dependent on the positioning of 
the innovation in the care pathway, and the recommendations 
for further research are strongly related to both the value 
proposition and positioning.
The current study focuses on the objective assessment of 
potential value for money of innovations. While we could not 
recommend not to pursue an innovation because all had some 
potential value, we subjectively could distinguish the more 
valuable from the less valuable innovations. Further research 
is needed to define objective criteria that help to prioritize 
innovations, such as the likelihood of an innovation closing 
the effectiveness gap, barriers for implementation, and 
existing uncertainty. In addition, it is interesting to see how 
these innovations proceed. First, the value of early economic 
modeling could be studied by exploring whether and how the 
clients of these assessments used the results. In a later stage, 
the early assessments could be validated when real-world 
evidence on the innovations becomes available. 
Our results contribute to the understanding and 
interpretation of early health economic modeling, and 
potentially to the way such modeling studies are performed. 
For most of the innovations assessed here, evidence on their 
(cost-)effectiveness is not yet required to become widely used. 
If this evidence becomes mandatory in the new European 
Union Medical Device Regulation, the role, use and timing 
of early HTA may become more clear-cut.22,23 Ideally, early 
HTA informs and thereby integrates development, research 
and implementation decisions, and bridges the gap between 
development and use of promising innovations.24 Regardless 
of the availability and requirement of evidence, we believe 
that the ultimate goal of early HTA should be to accept the 
existing uncertainty, try to understand it, and make it part 
of our reasoning.15 By using scenario analysis (including 
the best-case headroom scenario) it is possible to explore 
what could be the consequences of an innovation if certain 
assumptions (eg, regarding positioning or effectiveness) 
are made. This provides insight in how to proceed, both in 
terms of development of the innovation and further research. 
This implies a shift away from traditional use of health 
economic modeling with the aim of estimating the exact 
cost-effectiveness of a technology, towards exploring what is 
needed for a technology to provide most value for money.
Conclusion
Our exploration of 32 early health economic modeling 
assessments showed that the assessments provided insight 
in the size and uncertainty of the potential cost-effectiveness 
of an innovation in its intended context. Although we found 
differences between innovations in the magnitude of the 
potential cost-effectiveness, and the likelihood of reaching 
this potential, none of the assessments resulted in a firm 
‘no-go’ recommendation because they all were potentially 
cost-effective by improving health and/or saving costs. The 
assessments did provide insight in how to proceed, both in 
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terms of development and positioning of the innovation and 
further research, in order to maximize value for money.
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